Moderna mRNA-1273, COVID-19 vaccine

Overview

The Moderna COVID-19 vaccine is a messenger RNA (mRNA) based vaccine against coronavirus disease 2019 (COVID-19). The host cells receive the instruction from the mRNA to produce protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) and had negative baseline SARS-CoV-2 status, was approximately 94% based on a median follow-up of 9 weeks. The data reviewed at this time support the conclusion that the known and potential benefits of mRNA-1273 vaccine outweigh the known and potential risks. (Update pending)

Other languages available: